# reload+after+2024-01-22 10:45:15.236850
address1§1 Rockefeller Plaza
address2§Suite 1039
city§New York
state§NY
zip§10020
country§United States
phone§646 756 2997
website§https://www.hoththerapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
fullTimeEmployees§2
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robb  Knie', 'age': 54, 'title': 'President, CEO & Chairman', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 844009, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David S. Briones', 'age': 47, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Hayley  Springer', 'title': 'Executive Vice President of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.605
currency§USD
dateShortInterest§1702598400
forwardEps§-1.45
exchange§NCM
quoteType§EQUITY
shortName§Hoth Therapeutics, Inc.
longName§Hoth Therapeutics, Inc.
firstTradeDateEpochUtc§1550241000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ff6dafe1-fa0d-3a83-9121-424872ea93bf
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.5
targetLowPrice§3.0
targetMeanPrice§4.75
targetMedianPrice§4.75
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§7.507
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
